Ascelia Pharma AB financials
Ascelia Pharma AB
5493002YR9VCJJPWYN08 | Line item | 2024 | 2023 |
|---|---|---|
| Income statement | ||
| Revenue | SEK 0 | SEK 0 |
| Gross profit | SEK 0 | SEK 0 |
| Other income | SEK 459.0K | SEK 1.6M |
| Administrative expenses | SEK 18.0M | SEK 19.8M |
| Operating profit (EBIT) | -SEK 67.8M | -SEK 110.9M |
| Net finance income / (cost) | -SEK 12.4M | SEK 1.3M |
| Finance costs | SEK 13.9M | SEK 2.4M |
| Profit before tax | -SEK 80.1M | -SEK 109.6M |
| Income tax expense | -SEK 94.0K | -SEK 319.0K |
| Profit for the year | -SEK 80.0M | -SEK 109.3M |
| — attributable to owners | -SEK 80.0M | -SEK 109.3M |
| — attributable to NCI | SEK 0 | SEK 0 |
| Total comprehensive income | -SEK 79.7M | -SEK 109.6M |
| Per share | ||
| Basic EPS | SEK -1.48 | SEK -3.24 |
| Diluted EPS | SEK -1.48 | SEK -3.24 |
| Free cash flow / share | SEK -1.16 | SEK -3.76 |
| Cash flow statement | ||
| Net cash from operating activities | -SEK 62.8M | -SEK 126.8M |
| Net cash from investing activities | SEK 0 | SEK 47.0K |
| Purchase of PP&E (capex) | SEK 0 | SEK 0 |
| Net cash from financing activities | SEK 115.2M | -SEK 936.0K |
| Lease liability payments | SEK 887.0K | SEK 906.0K |
| Net change in cash | SEK 52.3M | -SEK 127.7M |
| Balance sheet | ||
| Total assets | SEK 140.9M | SEK 87.1M |
| Non-current assets | SEK 57.2M | SEK 58.1M |
| Property, plant & equipment | SEK 15.0K | SEK 89.0K |
| Right-of-use assets | SEK 109.0K | SEK 973.0K |
| Current assets | SEK 83.7M | SEK 28.9M |
| Cash & equivalents | SEK 75.3M | SEK 21.9M |
| Total equity | SEK 78.9M | SEK 74.3M |
| — attributable to owners | SEK 78.9M | SEK 74.3M |
| Non-current liabilities | SEK 0 | SEK 176.0K |
| Lease liabilities (non-current) | SEK 0 | SEK 176.0K |
| Current liabilities | SEK 62.0M | SEK 12.6M |
| Short-term borrowings | SEK 25.2M | SEK 0 |
| Lease liabilities (current) | SEK 172.0K | SEK 884.0K |
| Derived metrics | ||
| Free cash flow | -SEK 62.8M | -SEK 126.8M |
| Return on equity | -101.4% | -147.0% |
| Cash conversion ratio | 0.79× | 1.16× |
| Other reported items | ||
| Additional Paidin Capital | SEK 721.8M | SEK 678.7M |
| Adjustments For Decrease Increase In Other Current Assets | SEK 1.7M | SEK 1.9M |
| Adjustments For Decrease Increase In Trade and Other Receivables | -SEK 5.0M | SEK 1.6M |
| Adjustments For Increase Decrease In Other Liabilities | SEK 3.6M | -SEK 11.0M |
| Adjustments For Increase Decrease In Trade Account Payable | SEK 3.2M | -SEK 14.4M |
| Adjustments For Sharebased Payments | SEK 4.3M | SEK 2.9M |
| Cash Flows From Used In Operations Before Changes In Working Capital | -SEK 66.4M | -SEK 105.0M |
| Current Accruals and Current Deferred Income Including Current Contract Liabilities | SEK 12.7M | SEK 8.5M |
| Current Advances To Suppliers | SEK 1.8M | SEK 3.4M |
| Current Prepayments and Current Accrued Income Including Current Contract Assets | SEK 1.0M | SEK 1.2M |
| Current Tax Assets Current | SEK 632.0K | SEK 2.0M |
| Current Tax Liabilities Current | SEK 0 | SEK 0 |
| Effect of Exchange Rate Changes On Cash and Cash Equivalents | SEK 1.1M | -SEK 18.0K |
| Equity and Liabilities | SEK 140.9M | SEK 87.1M |
| Finance Income | SEK 1.6M | SEK 3.7M |
| Income Taxes Paid Refund Classified As Operating Activities | -SEK 1.5M | -SEK 1.2M |
| Increase Decrease In Working Capital | -SEK 3.5M | SEK 21.8M |
| Increase Decrease Through Exercise of Options | — | SEK 0 |
| Increase Decrease Through Sharebased Payment Transactions | SEK 4.4M | SEK 3.1M |
| Increase Decrease Through Transactions With Owners | SEK 84.3M | SEK 3.1M |
| Intangible Assets Other Than Goodwill | SEK 57.1M | SEK 57.1M |
| Interest Paid Classified As Operating Activities | SEK 5.2M | SEK 121.0K |
| Interest Received Classified As Operating Activities | SEK 773.0K | SEK 1.3M |
| Issue of Convertible Instruments | SEK 2.2M | — |
| Issued Capital | SEK 97.2M | SEK 34.9M |
| Liabilities | SEK 62.0M | SEK 12.7M |
| Other Adjustments For Noncash Items | SEK 49.0K | SEK 664.0K |
| Other Comprehensive Income | SEK 303.0K | -SEK 301.0K |
| Other Comprehensive Income Net of Tax Exchange Differences On Translation | SEK 303.0K | -SEK 301.0K |
| Other Current Liabilities | SEK 19.1M | SEK 1.6M |
| Other Current Receivables | SEK 5.1M | SEK 480.0K |
| Other Expense By Function | SEK 100.0K | SEK 1.0M |
| Payments For Share Issue Costs | SEK 15.2M | SEK 30.0K |
| Proceeds From Issue of Bonds Notes and Debentures | SEK 733.0K | SEK 0 |
| Proceeds From Issuing Shares | SEK 105.3M | SEK 0 |
| Research and Development Expense | SEK 50.8M | SEK 81.3M |
| Reserve of Exchange Differences On Translation | SEK 974.0K | SEK 671.0K |
| Retained Earnings | -SEK 741.0M | -SEK 640.0M |
| Share Issue Related Cost | SEK 15.2M | SEK 30.0K |
| Trade and Other Current Payables To Trade Suppliers | SEK 4.7M | SEK 1.5M |
Every line item above is a fact tagged in Ascelia Pharma AB's annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (SEK), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.